down arrow

Annexon, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03589W1027
USD
5.18
0.07 (1.37%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.115.29

52 Week

1.285.66
Valuation
Technical
Day's Volume

CASH

955.88 k

Shareholding (Mar 2025)

FII

22.39%

Held by 78 FIIs

DII

28.08%

Held by 49 DIIs

Promoter

12.90%

How big is Annexon, Inc.?

22-Jun-2025

As of Jun 18, Annexon, Inc. has a market capitalization of 256.73 million and reported net sales of 0.00 million with a net profit of -167.38 million over the last four quarters. Shareholder's funds were valued at 293.11 million, and total assets amounted to 350.07 million.

As of Jun 18, Annexon, Inc. has a market capitalization of 256.73 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -167.38 million during the same period.<BR><BR>As of Dec 24, the shareholder's funds were valued at 293.11 million, and total assets amounted to 350.07 million.

Read More

What does Annexon, Inc. do?

22-Jun-2025

Annexon, Inc. is a clinical-stage biopharmaceutical company developing therapies for classical complement-mediated disorders, with a market cap of approximately $256.73 million and a recent net profit of -$54 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

Overview: <BR>Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for classical complement-mediated disorders in the body, brain, and eye, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -54 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 256.73 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.07 <BR>Return on Equity: -68.66% <BR>Price to Book: 1.05<BR><BR>Contact Details: <BR>Address: 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA: 94080 <BR>Tel: 1 650 8225500 <BR>Fax: 1 650 6369773 <BR>Website: http://www.annexonbio.com/

Read More

Who are in the management team of Annexon, Inc.?

22-Jun-2025

As of March 2022, Annexon, Inc.'s management team includes CEO Douglas Love and Independent Chairman William Young, along with several independent directors: Jung Choi, Emmett Cunningham, Carol Gallagher, and Muneer Satter.

As of March 2022, the management team of Annexon, Inc. includes the following individuals:<BR><BR>- Mr. William Young, who serves as the Independent Chairman of the Board.<BR>- Mr. Douglas Love, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Jung Choi, who is an Independent Director.<BR>- Dr. Emmett Cunningham, who is also an Independent Director.<BR>- Dr. Carol Gallagher, another Independent Director.<BR>- Mr. Muneer Satter, who is an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Mr. Douglas Love holding the key executive role as CEO.

Read More

Is Annexon, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Annexon, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a 1-year return of -61.90% compared to 17.14%.

As of 10 September 2025, the technical trend for Annexon, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook, while the weekly MACD and Dow Theory show a mildly bullish sentiment. The Bollinger Bands on a weekly basis are bullish, but the monthly indicators present a mixed picture with bearish signals. <BR><BR>In terms of performance, the stock has underperformed significantly against the S&P 500 over the longer term, with a 1-year return of -61.90% compared to the S&P 500's 17.14%, and a 5-year return of -88.27% versus 96.61% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 243 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.13

stock-summary
Return on Equity

-93.92%

stock-summary
Price to Book

1.22

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-49 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
83.69%
0%
83.69%
6 Months
111.43%
0%
111.43%
1 Year
-0.96%
0%
-0.96%
2 Years
29.18%
0%
29.18%
3 Years
-4.95%
0%
-4.95%
4 Years
-59.66%
0%
-59.66%
5 Years
-82.72%
0%
-82.72%

Annexon, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-221.86%
EBIT to Interest (avg)
-133.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.17
EV to EBIT
-0.13
EV to EBITDA
-0.13
EV to Capital Employed
-1.40
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-68.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 46 Schemes (36.63%)

Foreign Institutions

Held by 78 Foreign Institutions (22.39%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -66.22% vs 15.91% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-50.80",
          "val2": "-32.70",
          "chgp": "-55.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.20",
          "val2": "-29.60",
          "chgp": "-66.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2.98% vs 5.43% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-150.60",
          "val2": "-140.50",
          "chgp": "-7.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-138.20",
          "val2": "-134.20",
          "chgp": "-2.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-50.80
-32.70
-55.35%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-49.20
-29.60
-66.22%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -66.22% vs 15.91% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-150.60
-140.50
-7.19%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-138.20
-134.20
-2.98%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2.98% vs 5.43% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Annexon, Inc. stock-summary
stock-summary
Annexon, Inc.
Pharmaceuticals & Biotechnology
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of therapies for patients with classical complement-mediated disorders of the body, brain and eye. The Company’s pipeline is based on its platform technology addressing classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its product candidate, ANX005, is a monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Its product candidate, ANX007, is an antigen-binding fragment (Fab), formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. It is also developing ANX009, an investigational, subcutaneous formulation of a Fab designed for the treatment of systemic autoimmune diseases.
Company Coordinates stock-summary
Company Details
180 KIMBALL WAY, SUITE 200 , SOUTH SAN FRANCISCO CA : 94080
stock-summary
Tel: 1 650 8225500
stock-summary
http://www.annexonbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."